Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome

Sponsor
National Institute of Dental and Craniofacial Research (NIDCR) (NIH)
Overall Status
Recruiting
CT.gov ID
NCT00001727
Collaborator
(none)
500
1

Study Details

Study Description

Brief Summary

Polyostotic fibrous dysplasia (PFD) is a sporadic disorder which affects multiple sites in the skeleton. The bone at these sites is rapidly resorbed and replaced by abnormal fibrous tissue or mechanically abnormal bone. PFD may occur alone or as part of the McCune-Albright Syndrome (MAS), a syndrome originally defined by the triad of PFD, cafe-au-lait pigmentation of the skin, and precocious puberty. The bony lesions are frequently disfiguring, disabling and painful, and depending on the location of the lesion, can cause significant morbidity. Lesions in weight-bearing bones can lead to disabling fractures, while lesions in the skull can lead to compression of vital structures such as cranial nerves.

The natural history of this disease is poorly described and there are no clearly defined systemic therapies for the bone disease. This is a data collection and specimen acquisition protocol. The purpose of the study is to define the natural history of the disease by following PFD/MAS subjects over time and by using in vitro experimentation with samples/tissue from subjects with the disease.

Study Objectives

  1. Primary Objective

Define the natural history of disease by gaining clinical and basic information about PFD/MAS by following subjects clinically and using in vitro experimentation with tissue from subjects with the disease.

  1. Secondary Objective

Refer eligible subjects for enrollment into other appropriate research protocols, if any are currently active.

Study Population

The study population will include:
  1. Subjects with known or suspected Polyostotic Fibrous Dysplasia (PFD) or in combination with McCune-Albright Syndrome (MAS)

  2. Subjects who meet eligibility criteria will be accepted regardless of gender, race, or ethnicity

Design

This study is an observational/natural history study of PFD/MAS.

Outcome Measures

Primary

  1. Successfully enroll subjects with PFD or MAS for the collection, evaluation and analysis of data obtained from clinical visits.

  2. Obtain onsite and offsite research tissue (waste tissue) from patients with PFD/MAS that are enrolled onto this study or from individuals with PFD/MAS that are offsite and willing to donate waste tissue to NIH. Research tissue will be used with existing primary cell culture technology (ongoing in our laboratories) to:

  • understand the basic bone biology of the pathologic cell (or cells) involved in the lesions of PFD/MAS

  • determine the presence or absence of mutated cells at "uninvolved sites" to formulate better strategies of predicting the initiation of new lesions, the natural history of lesion progression and/or response to therapy

  • understand osteogenic differentiation, in particular, the role of G(s)alpha in these lesions, which will be transferable to our understanding of bone biology in general

  • understand the pathophysiology of FD and/or endocrine lesions

  • develop better methods of identifying and expanding unaffected bone cells from patients with PFD in an effort to create better grafting material(s)

  1. Identify and predict clinical and biological behavior of fibrous dysplastic bone lesions based on:
  • stability, rate of growth, rate of change, progression and regression, and development of new lesions

  • differences between cranial, axial and appendicular lesions

  1. Define the natural history of the multiple endocrinopathies associated with MAS and the response to standard of care medications

  2. Define clinical and biological aspects of the disease not previously identified

  3. Generate future research studies related to PFD alone or in combination with MAS

Secondary

  1. Successfully enroll eligible subjects into active research protocols applicable to the FD/MAS population.
Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Polyostotic fibrous dysplasia (PFD) is a sporadic disorder which affects multiple sites in the skeleton. The bone at these sites is rapidly resorbed and replaced by abnormal fibrous tissue or mechanically abnormal bone. PFD may occur alone or as part of the McCune-Albright Syndrome (MAS), a syndrome originally defined by the triad of PFD, cafe-au-lait pigmentation of the skin, and precocious puberty. The bony lesions are frequently disfiguring, disabling and painful, and depending on the location of the lesion, can cause significant morbidity. Lesions in weight-bearing bones can lead to disabling fractures, while lesions in the skull can lead to compression of vital structures such as cranial nerves.

    The natural history of this disease is poorly described and there are no clearly defined systemic therapies for the bone disease. This is a data collection and specimen acquisition protocol. The purpose of the study is to define the natural history of the disease by following PFD/MAS subjects over time and by using in vitro experimentation with samples/tissue from subjects with the disease.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    500 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome
    Actual Study Start Date :
    Dec 13, 1998

    Arms and Interventions

    Arm Intervention/Treatment
    1

    Subjects with Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome.

    Outcome Measures

    Primary Outcome Measures

    1. Primary Objective: Define the natural history of disease by gaining clinical and basic information about PFD/MAS by following patients clinically and using in vitro experimentation with tissue from patients with the disease. [2029]

      Successfully enroll, evaluate, and manage subjects with Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome.

    Secondary Outcome Measures

    1. Refer eligible patients for enrollment into other appropriate research protocols, if any are currently active. [end of study]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    1 Day and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    • INCLUSION CRITERIA
    1. Any patient, age 1 day of life and older, with a likelihood of having PFD or MAS, based on information from an appropriate referring physician or surgeon or provided by the patient or guardian. The diagnosis will be based on typical findings on bone biopsy or on clinical grounds.

    EXCLUSION CRITERIA

    1. Patient, child or parent/guardian unwilling to fully cooperate with the evaluations.

    2. Patient or parent/guardian unable to provide informed consent.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 National Institutes of Health Clinical Center Bethesda Maryland United States 20892

    Sponsors and Collaborators

    • National Institute of Dental and Craniofacial Research (NIDCR)

    Investigators

    • Principal Investigator: Alison M Boyce, M.D., National Institute of Dental and Craniofacial Research (NIDCR)

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    National Institute of Dental and Craniofacial Research (NIDCR)
    ClinicalTrials.gov Identifier:
    NCT00001727
    Other Study ID Numbers:
    • 980145
    • 98-D-0145
    First Posted:
    Nov 4, 1999
    Last Update Posted:
    Aug 19, 2022
    Last Verified:
    Aug 3, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by National Institute of Dental and Craniofacial Research (NIDCR)
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 19, 2022